Document:

EX-4.2

 Exhibit 4.2 

SINGULAR GENOMICS SYSTEMS, INC. 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

June 27, 2019 

  
  

1 

 TABLE OF CONTENTS 

 

					
		  	 	Page	 
	 1.  Definitions
	  	 	1	 
		
	 2.  Registration Rights
	  	 	3	 
	 2.1   Request for Registration
	  	 	3	 
	 2.2   Company Registration
	  	 	5	 
	 2.3   Form S-3 Registration
	  	 	6	 
	 2.4   Obligations of the Company
	  	 	8	 
	 2.5   Information from Holder
	  	 	9	 
	 2.6   Expenses of Registration
	  	 	9	 
	 2.7   Delay of Registration
	  	 	9	 
	 2.8   Indemnification
	  	 	10	 
	 2.9   Reports Under the 1934 Act
	  	 	12	 
	 2.10  Assignment of Registration Rights
	  	 	12	 
	 2.11  Limitations on Subsequent Registration Rights
	  	 	13	 
	 2.12  “Market Stand-Off”
Agreement
	  	 	13	 
	 2.13  Termination of Registration Rights
	  	 	14	 
		
	 3.  Covenants of the Company
	  	 	14	 
	 3.1   Delivery of Financial Statements
	  	 	14	 
	 3.2   Inspection
	  	 	15	 
	 3.3   Termination of Information and Inspection Covenants
	  	 	16	 
	 3.4   Right of First Offer
	  	 	16	 
	 3.5   Directors’ and Officers’ Insurance
	  	 	17	 
	 3.6   Board Matters
	  	 	17	 
	 3.7   Proprietary Information and Inventions Agreements
	  	 	17	 
	 3.8   Employee Agreements
	  	 	18	 
	 3.9   Qualified Small Business Stock
	  	 	18	 
	 3.10  Right to Conduct Activities
	  	 	18	 
	 3.11  Termination of Certain Covenants
	  	 	19	 
		
	 4.  Miscellaneous
	  	 	19	 
	 4.1   Successors and Assigns
	  	 	19	 
	 4.2   Governing Law
	  	 	19	 
	 4.3   Counterparts; Electronic Signature
	  	 	19	 
	 4.4   Titles and Subtitles
	  	 	19	 
	 4.5   Notices
	  	 	19	 
	 4.6   Expenses
	  	 	20	 
	 4.7   Entire Agreement; Amendments
	  	 	20	 
	 4.8   Severability
	  	 	20	 
	 4.9   Aggregation of Stock
	  	 	20	 
	 4.10  Additional Investors
	  	 	21	 
	 4.11  Effect on Prior Agreement
	  	 	21	 

 SCHEDULE A      Schedule of Investors 

 SCHEDULE B      Schedule of Common Holders 

  
 2 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as June 27, 2019, by and among
Singular Genomics Systems, Inc., a Delaware corporation (the “Company”), the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and collectively as
the “Investors”, and each of the stockholders listed on Schedule B hereto, each of whom is herein referred to as a “Common Holder” and collectively as the “Common Holders”. 

RECITALS 
 WHEREAS,
certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series Seed Preferred Stock, par value $0.0001 per share (the “Series Seed Preferred Stock”) and/or Series A Preferred Stock, par
value $0.0001 per share (the “Series A Preferred Stock”), and possess registration rights, information rights, rights of first offer and other rights pursuant to that certain Amended and Restated Investors’ Rights Agreement
dated as of June 20, 2017, by and among the Company, such Existing Investors and the Common Holders (the “Prior Agreement”); 

WHEREAS, the Prior Agreement may be amended, and any provision therein waived, as set forth herein with the consent of the Company and
the holders of at least 65% of the Registrable Securities (as such term is defined in the Prior Agreement); 
 WHEREAS, the requisite
parties desire to amend and restate the Prior Agreement and to accept the rights created pursuant hereto in lieu of the rights granted to them under the Prior Agreement; 

WHEREAS, the Company and certain Investors (the “New Investors”) are parties to that certain Series B Preferred Stock
Purchase Agreement of even date herewith (the “Purchase Agreement”); and 
 WHEREAS, in order to induce the New
Investors to purchase Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock” and, together with the Series Seed Preferred Stock and the Series A Preferred Stock, the “Preferred
Stock”), and invest funds in the Company pursuant to the Purchase Agreement, the New Investors, the undersigned Existing Investors, and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the
Company to register shares of Common Stock, par value $0.0001 per share (the “Common Stock”), issued or issuable to them and certain other matters as set forth herein. 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Company and the undersigned Existing
Investors hereby agree that the Prior Agreement is superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follow: 

1. Definitions. For purposes of this Agreement: 

 (a) The term “Act” means the Securities Act of 1933, as amended. 

(b) The term “Affiliate” means, with respect to any specified Person, any other Person who or which, directly or indirectly,
controls, is controlled by, or is under common control with such specified Person, including without limitation any stockholder, partner, officer, director, member or employee of such Person and any venture capital fund now or hereafter existing
that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company or advisory company with, such Person. 

(c) The term “Board” means the Company’s Board of Directors, as constituted from time to time. 

(d) The term “Form S-3” means such form under the Act as in
effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(e) The term “Free Writing Prospectus” means a free-writing prospectus, as defined in Rule 405. 

(f) The term “Holder” means any Person owning or having the right to acquire Registrable Securities or any assignee thereof
in accordance with Section 2.10 of this Agreement; provided, however, that the Common Holders shall not be deemed to be Holders for purposes of Sections 2.1, 2.3, 2.11 and 4.7. 

(g) The term “Initial Offering” means the Company’s first firm commitment underwritten public offering of its Common
Stock under the Act. 
 (h) The term “1934 Act” means the Securities Exchange Act of 1934, as amended. 

(i) The term “Person” shall mean any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 (j) The terms “register,” “registered,” and “registration” refer to a
registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document. 

(k) The term “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred
Stock, (ii) Common Stock held by the Investors, (iii) Common Stock held by the Common Holders; provided, however, that such shares of Common Stock held by the Common Holders shall not be deemed Registrable Securities for the
purposes of Sections 2.1, 2.3, 2.11, 3.1, 3.2, 3.4 and 4.7 and (iv) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for, or in replacement of, the shares referenced in (i), (ii) and (iii) above, excluding in all cases, however, any 

  
 2 

 
Registrable Securities sold by a Person in a transaction in which his rights under Section 2 of this Agreement are not assigned. In addition, the number of shares of Registrable Securities
outstanding shall equal the aggregate of the number of shares of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities that are, Registrable Securities. 

(l) The term “Restated Certificate” shall mean the Company’s Restated Certificate of Incorporation, as amended and/or
restated from time to time. 
 (m) The term “Rule 144” shall mean Rule 144 under the Act. 

(n) The term “Rule 144(b)(1)(i)” shall mean subsection (b)(1)(i) of Rule 144 under the Act as it applies to Persons who have
held shares for more than one (1) year. 
 (o) The term “Rule 405” shall mean Rule 405 under the Act. 

(p) The term “SEC” shall mean the Securities and Exchange Commission. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Request for Registration. 

(a) Subject to the conditions of this Section 2.1, if the Company shall receive at any time after the earlier of (i) three (3)
years following the date hereof or (ii) the six (6) month anniversary of the effective date of the Initial Offering, a written request from the Holders of at least thirty five percent (35%) of the Registrable Securities then outstanding
(for purposes of this Section 2.1, the “Initiating Holders”) that the Company file a registration statement under the Act covering the registration of Registrable Securities with an anticipated aggregate offering price of at
least $10,000,000, then the Company shall, within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 2.1, use its commercially reasonable efforts to
effect, as soon as practicable but in any event within sixty (60) days, the registration under the Act of all Registrable Securities that the Holders request to be registered in a written request received by the Company within twenty
(20) days of the mailing of the Company’s notice pursuant to this Section 2.1(a). 
 (b) If the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.1, and the Company shall include such information in the
written notice referred to in Section 2.1(a). In such event the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of
such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to those
Initiating Holders holding a majority of the Registrable Securities then held by all Initiating 

  
 3 

 
Holders). Notwithstanding any other provision of this Section 2.1, if the underwriter advises the Company that marketing factors require a limitation on the number of securities underwritten
(including Registrable Securities), then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to
the Holders of such Registrable Securities pro rata based on the number of Registrable Securities held by all such Holders (including the Initiating Holders). In no event shall any Registrable Securities be excluded from such underwriting unless all
other securities are first excluded. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

(c) Notwithstanding the foregoing, the Company shall not be required to effect a registration pursuant to this Section 2.1: 

(i) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting
such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act; or 

(ii) after the Company has effected two (2) registrations pursuant to this Section 2.1, and such registrations have been declared
or ordered effective; or 
 (iii) during the period starting with the date sixty (60) days prior to the Company’s good faith
estimate of the date of the filing of and ending on a date one hundred eighty (180) days following the effective date of a Company-initiated registration subject to Section 2.2 below, provided
that the Company is actively employing in good faith its commercially reasonable efforts to cause such registration statement to become effective; or 

(iv) if the Initiating Holders propose to dispose of Registrable Securities that may be registered on
Form S-3 pursuant to Section 2.3 hereof; or 
 (v) if the Company shall furnish to
Holders requesting a registration statement pursuant to this Section 2.1 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously
detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of
the request of the Initiating Holders; provided that such right shall be exercised by the Company not more than once in any twelve (12) month period; and provided further that the Company shall not register any securities
for the account of itself or any other stockholder during such ninety (90) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate
reorganization or transaction under Rule 145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered). 

  
 4 

 (d) For purposes of Subsection 2.1(c)(ii), a registration shall be counted as
“effected” only if (i) all Registrable Securities requested to be included pursuant to Subsection 2.1(a) are registered or (ii) such registration request is withdrawn at the request of the Holders or a majority of the Registrable
Securities to be registered (other than as a result of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request of the registration). 

2.2 Company Registration. 

(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the
Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities (other than (i) a registration relating to a demand pursuant to Section 2.1 of
this Agreement or (ii) a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any
form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within twenty
(20) days after mailing of such notice by the Company in accordance with Section 4.5 of this Agreement, the Company shall, subject to the provisions of Section 2.2(c) of this Agreement, use its commercially reasonable efforts to cause
to be registered under the Act all of the Registrable Securities that each such Holder requests to be registered. 
 (b) Right to
Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include
securities in such registration. The expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2.6 hereof. 

(c) Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital
stock, the Company shall not be required under this Section 2.2 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters
selected by the Company (or by other Persons entitled to select the underwriters) and enter into an underwriting agreement in customary form with such underwriters, and then only in such quantity as the underwriters determine in their sole
discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other
than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable
Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. In the event that the underwriters determine that less than all of the Registrable Securities requested to be registered can be
included in such offering, then the Registrable Securities that are included 

  
 5 

 
in such offering shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually
be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) any Registrable Securities be excluded from such offering unless all other stockholders’ securities have been first excluded from the offering,
(ii) the amount of securities of the selling Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless such offering is the Initial Offering, in which case the
selling Holders may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included in such offering or (iii) any securities held by a Common Holder be included in such offering if
any Registrable Securities held by any Holder other than a Common Holder (and that such Holder has requested to be registered) are excluded from such offering. For purposes of the preceding sentence concerning apportionment, for any selling
stockholder that is a Holder of Registrable Securities and that is a venture capital fund, partnership or corporation, the affiliated venture capital funds, partners, members, retired partners and stockholders of such Holder, or the estates and
family members of any such partners, members and retired partners and any trusts for the benefit of any of the foregoing Persons shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling
Holder” shall be based upon the aggregate amount of Registrable Securities owned by all such related entities and individuals. 
 2.3
Form S-3 Registration. In case the Company shall receive from the Holders of at least twenty percent (20%) of the Registrable Securities (for purposes of this Section 2.3, the
“S-3 Initiating Holders”) a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the
Registrable Securities owned by such Holder or Holders, the Company shall: 
 (a) promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders; and 
 (b) use its commercially reasonable efforts to
effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders’ Registrable Securities as
are specified in such request, together with all or such portion of the Registrable Securities of any other Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written
notice from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 2.3: 

(i) if Form S-3 is not available for such offering by the Holders; 

(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $1,000,000; 

  
 6 

 (iii) if the Company shall furnish to all Holders requesting a registration statement
pursuant to this Section 2.3 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders
for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the
S-3 Initiating Holders; provided that such right shall be exercised by the Company not more than once in any twelve (12) month period; and provided further that the Company shall not
register any securities for the account of itself or any other stockholder during such ninety (90) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating
to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the
Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered); 

(iv) if the Company has, within the twelve (12) month period preceding the date of such request, already effected two
(2) registrations on Form S-3 pursuant to this Section 2.3; 
 (v) in any particular
jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance; 

(vi) if the Company, within thirty (30) days of receipt of the request of such S-3 Initiating
Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the SEC within one hundred twenty (120) days of receipt of such request (other than a registration effected solely to qualify an employee
benefit plan or to effect a business combination pursuant to Rule 145), provided that the Company is actively employing in good faith its commercially reasonable efforts to cause such registration statement to become effective; or 

(vii) during the period starting with the date thirty (30) days prior to the Company’s good faith estimate of the date of the
filing of and ending on a date ninety (90) days following the effective date of a Company-initiated registration subject to Section 2.2 of this Agreement, provided that the Company is actively
employing in good faith its commercially reasonable efforts to cause such registration statement to become effective. 
 (c) If the S-3 Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this
Section 2.3 and the Company shall include such information in the written notice referred to in Section 2.3(a). The provisions of Section 2.1(b) of this Agreement shall be applicable to such request (with the substitution of
Section 2.3 for references to Section 2.1). 
 (d) Subject to the foregoing, the Company shall file a registration statement
covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the S-3 Initiating Holders. Registrations effected
pursuant to this Section 2.3 shall not be counted as requests for registration effected pursuant to Section 2.1 of this Agreement. 

  
 7 

 2.4 Obligations of the Company. Whenever required under this Section 2 to effect
the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with
the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the Registration Statement has been completed; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement; 

(c) furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus and any Free Writing Prospectus, in
conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions; 
 (e) in the event of any underwritten public offering, enter
into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering; 

(f) notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus or Free Writing
Prospectus (to the extent prepared by or on behalf of the Company) relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, and, at the request
of any such Holder, the Company will, as soon as reasonably practicable, file and furnish to all such Holders a supplement or amendment to such prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) so that, as
thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading in light of the
circumstances under which they were made; 

  
 8 

 (g) cause all such Registrable Securities registered pursuant to this Section 2 to be
listed on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed; and 

(h) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration. 
 In the event of the suspension of
effectiveness of any registration statement pursuant to this Section 2.4, the applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of days the
effectiveness of such registration statement was suspended. 
 2.5 Information from Holder. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses other than underwriting discounts and commissions incurred in connection with registrations,
filings or qualifications pursuant to Sections 2.1, 2.2 and 2.3 of this Agreement, including, without limitation, all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the
Company and the reasonable fees and disbursements of one counsel for the selling Holders shall be borne by the Company. Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any registration proceeding begun
pursuant to Section 2.1 or Section 2.3 of this Agreement if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating
Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration) unless, in the case of a registration requested under Section 2.1 of this Agreement, the Holders
of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 2.1 of this Agreement and; provided, however, that if at the time of such withdrawal, the Holders have learned
of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such
material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Sections 2.1 and 2.3 of this Agreement. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

  
 9 

 2.8 Indemnification. In the event any Registrable Securities are included in a
registration statement under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each
Holder, the partners, members, officers, directors and stockholders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Act) for such Holder and each Person, if any, who controls such Holder or
underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act, any state securities laws or any rule or regulation
promulgated under the Act, the 1934 Act or any state securities laws, insofar as such losses, claims, damages, or liabilities (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any of the
following statements, omissions or violations (collectively, a “Violation”): (i) any untrue or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus, final
prospectus, or Free Writing Prospectus contained therein or any amendments or supplements thereto, any issuer information (as defined in Rule 433 of the Act) filed or required to be filed pursuant to Rule 433(d) under the Act or any other document
incident to such registration prepared by or on behalf of the Company or used or referred to by the Company, (ii) the omission or alleged omission of a material fact required to be stated in such registration statement, or necessary to make the
statements therein not misleading or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, and
the Company will reimburse each such Holder, underwriter, controlling Person or other aforementioned Person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage,
liability, action or proceeding as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability, action or proceeding if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability,
action or proceeding to the extent that it arises out of or is based upon a Violation that occurs in reliance upon, and in conformity with, written information furnished expressly for use in connection with such registration by any such Holder,
underwriter, controlling Person or other aforementioned Person. 
 (b) To the extent permitted by law, each selling Holder, severally and
not jointly, will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of the Act, legal counsel and
accountants for the Company, any underwriter, any other Holder selling securities in such registration statement and any controlling Person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or
several) to which any of the foregoing Persons may become subject, under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, insofar as such losses, claims,
damages or liabilities (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and
in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any Person 

  
 10 

 
intended to be indemnified pursuant to this Section 2.8(b) for any legal or other expenses reasonably incurred by such Person in connection with investigating or defending any such loss,
claim, damage, liability, action or proceeding as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability, action or proceeding if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld), and provided that in no event shall any indemnity under this Section 2.8(b),
when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(d), exceed the net proceeds from the offering received by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action or proceeding
(including any governmental action or proceeding) for which a party may be entitled to indemnification, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver to
the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed,
to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one (1) separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to
actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement
of any such action or proceeding, if prejudicial to its ability to defend such action or proceeding, shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8 to the extent of such prejudice, but the
omission to so deliver written notice to the indemnifying party will not relieve such indemnifying party of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d) If the indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand in connection
with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; provided, however, that (i) no contribution by any Holder, when combined
with any amounts paid by such Holder pursuant to Section 2.8(b), shall exceed the net proceeds from the offering received by such Holder and (ii) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when
combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any expenses paid by such Holder). The relative fault of the

  
 11 

 
indemnifying party and the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) The obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 2 unless superseded by an underwriting agreement. 
 2.9 Reports Under the
1934 Act. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration
or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and keep public
information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the Initial Offering; 

(b) file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it
has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested to avail any Holder of any rule or regulation of the SEC that
permits the selling of any such securities without registration or pursuant to such form. 
 2.10 Assignment of Registration Rights.
The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities that (a) is another Holder,
(b) is an Affiliate, subsidiary, parent, partner, limited partner, retired partner, member or stockholder of a Holder, (c) is a Holder’s family member or trust for the benefit of an individual Holder or any of such Holder’s
family members, or (d) acquires at least thirty percent (30%) of the Registrable Securities originally held by the transferring Holder, provided: (i) the Company is, within a reasonable time after such transfer, furnished with
written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (ii) such transferee or assignee agrees in writing to be bound by and subject to the
terms and conditions of this Agreement, including, without limitation, the provisions of Section 2.12 of this Agreement; and (iii) such assignment shall be effective only if immediately following such transfer the further disposition of
such securities by the transferee or assignee is restricted under the Act. 

  
 12 

 2.11 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders holding a majority of the Registrable Securities then held by all Holders including the holders of a majority of the then outstanding Series B Preferred Stock, enter
into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (a) to include any of such securities in any registration filed under Section 2.1,
Section 2.2 or Section 2.3 of this Agreement, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will
not reduce the amount of the Registrable Securities of the Holders that are included or (b) to demand registration of their securities. 

2.12 “Market Stand-Off” Agreement. 

(a) Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing
on the date of the final prospectus relating to the Initial Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days) (i) lend, offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock held immediately prior to the date of the final prospectus relating to the Initial Offering, or (ii) enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or
otherwise. The foregoing provisions of this Section 2.12 shall apply only to the Initial Offering, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if
all officers, directors and greater than one percent (1%) stockholders of the Company enter into similar agreements. The underwriters in connection with the Initial Offering are intended third-party
beneficiaries of this Section 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the
underwriters in the Initial Offering that are consistent with this Section 2.12 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or
the underwriters shall apply to all Holders subject to such agreements pro rata based on the number of shares subject to such agreements. 

In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with
respect to the Registrable Securities of each Holder (and the shares or securities of every other Person subject to the foregoing restriction) until the end of such period. 

  
 13 

 (b) Each Holder agrees that a legend reading substantially as follows shall be placed on
all certificates or electronic certificates representing all Registrable Securities of each Holder (and the shares or securities of every other Person subject to the restriction contained in this Section 2.12): 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD AFTER THE EFFECTIVE DATE
OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 
 2.13 Termination of Registration
Rights. No Holder shall be entitled to exercise any right provided for in this Section 2: (a) after five (5) years following the consummation of the Qualified Public Offering (as defined in the Restated Certificate), (b) as to any
Holder, such earlier time after the Initial Offering at which such Holder (x) can sell all shares held by it in compliance with Rule 144(b)(1)(i) or (y) holds one percent (1%) or less of the Company’s outstanding Common Stock and
all Registrable Securities held by such Holder (together with any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) can be sold in any three (3) month period without registration in compliance with
Rule 144 or (c) after the consummation of a Liquidation Event (other than an Asset Sale), as such terms are defined in the Restated Certificate. 

3. Covenants of the Company. 

3.1 Delivery of Financial Statements. 

(a) The Company shall, upon request, deliver to each Investor (or transferee of an Investor) that holds at least 161,656 shares of
Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) (a “Major Investor”): 

(i) as soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company, an income statement for such
fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in
reasonable detail, prepared in accordance with generally accepted accounting principles (“GAAP”), and, unless such requirement is waived by the Board including both Preferred Directors (as defined in the Restated Charter), audited
and certified by independent public accountants of nationally recognized standing selected by the Company; 
 (ii) as soon as practicable,
but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the Company, an unaudited income statement and statement of cash flows for such fiscal quarter and an unaudited balance sheet (and, on request, a
statement of stockholders’ equity) as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (A) be subject to normal year-end audit
adjustments and (B) not contain all notes thereto that may be required in accordance with GAAP); 

  
 14 

 (iii) as soon as practicable, but in any event within forty-five (45) days after the
end of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the
period (including, in the case of convertible debt securities, the face amount, issue date, maturity date, interest rate, conversion discount and valuation cap to the extent applicable), the Common Stock issuable upon conversion or exercise of any
outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all
in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 
 (iv)
within thirty (30) days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet (and, on request, statement of stockholder’s equity) as of the end of such month,
all prepared in accordance with GAAP (except that such financial statements may (A) be subject to normal year-end audit adjustments and (B) not contain all notes thereto that may be required in
accordance with GAAP); 
 (v) as soon as practicable, but in any event at least thirty (30) days prior to the end of each fiscal year,
a budget for the next fiscal year; and 
 (vi) such other information relating to the financial condition, business or corporate affairs of
the Company as the Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this subsection (v) to provide information that (A) is non-financial information that it deems in good faith to be a trade secret or similar confidential information or (B) the disclosure of which would adversely affect the attorney-client privilege between the
Company and its counsel. 
 (b) Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the
information set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to
comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing
its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall
permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers,
all at such reasonable times as may be requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that (A) is non-financial information that it deems in good faith to be a trade secret or similar confidential information or (B) the disclosure of which would adversely affect the attorney-client privilege between the
Company and its counsel. 

  
 15 

 3.3 Termination of Information and Inspection Covenants. The covenants set forth in
Sections 3.1 and 3.2 shall terminate and be of no further force or effect upon the earlier to occur of (a) the consummation of the Company’s first sale of its Common Stock or other securities pursuant to a registration statement under
the Act (other than a registration statement relating either to sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar plan or a SEC Rule 145 transaction), (b) when the Company first becomes
subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first occur and (c) the consummation of a Liquidation Event (other than an Asset Sale), as such terms are defined in the
Restated Certificate. 
 3.4 Right of First Offer. Subject to the terms and conditions specified in this Section 3.4, the
Company hereby grants to each Major Investor (a “ROFO Investor”) a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For purposes of this Section 3.4, the term
“ROFO Investor” includes any general partners and Affiliates of a ROFO Investor. The rights provided in this Section 3.4 may not be assigned or transferred by any ROFO Investor, except that a ROFO Investor shall be entitled to
apportion the right of first offer hereby granted it among itself and its partners and Affiliates in such proportions as it deems appropriate. 

Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, its
capital stock (including, without limitation, any such shares or securities issued in connection with debt securities) (“Shares”), the Company shall first make an offering of such Shares to each ROFO Investor in accordance with the
following provisions: 
 (a) The Company shall deliver a notice in accordance with Section 4.5 (“Notice”) to the ROFO
Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered and (iii) the price and terms upon which it proposes to offer such Shares. 

(b) By written notification received by the Company within twenty (20) calendar days after the giving of Notice, each ROFO Investor may
elect to purchase, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of Registrable Securities issued and held by such ROFO Investor (assuming full
conversion and exercise of all convertible and exercisable securities then outstanding) bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all convertible and exercisable
securities then outstanding and excluding all shares reserved and/or available for issuance under any and all equity incentive plans to the extent such shares are not then subject to outstanding awards under such plan(s)). At the expiration of such
twenty (20) calendar day period, the Company shall promptly, in writing, notify each ROFO Investor that elects to purchase all the shares available to it (a “Fully Exercising Investor”) of any other ROFO Investor’s failure
to do likewise. During the ten (10) calendar day period commencing after the Company has given such 

  
 16 

 
notice to the Fully Exercising Investors, each Fully Exercising Investor may elect to purchase that portion of the Shares for which ROFO Investors were entitled to subscribe, but which were not
subscribed for by the ROFO Investors, that is equal to the proportion that the number of shares of Registrable Securities issued and held by such Fully Exercising Investor bears to the total number of shares of Common Stock issued and held, or
issuable upon conversion of the Preferred Stock then held, by all Fully Exercising Investors who wish to purchase some of the unsubscribed shares. 

(c) If all Shares that ROFO Investors are entitled to obtain pursuant to Section 3.4(b) of this Agreement are not elected to be obtained
as provided in Section 3.4(b) of this Agreement, the Company may, during the ninety (90) day period following the expiration of the period provided in Section 3.4(b) of this Agreement, offer the remaining unsubscribed portion of such
Shares to any Person or Persons at a price not less than that, and upon terms no more favorable to the offeree than those, specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if
such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the ROFO Investors in accordance
herewith. 
 (d) The right of first offer in this Section 3.4 shall not be applicable to Excluded Issuances (as defined in the
Restated Certificate) or the sale of Series B Preferred Stock pursuant to the Purchase Agreement, as it may be amended from time to time in accordance with its terms. In addition to the foregoing, the right of first offer in this Section 3.4
shall not be applicable with respect to any ROFO Investor in any subsequent offering of Shares if (A) at the time of such offering, the ROFO Investor is not an “accredited investor,” as that term is then defined in Rule 501(a) of the
Act and (B) such offering of Shares is otherwise being offered only to accredited investors. 
 (e) The covenants set forth in this
Section 3.4 shall terminate and be of no further force or effect upon the consummation of (i) the Company’s Qualified Public Offering or (ii) a Liquidation Event (other than an Asset Sale), in each case, as such term is defined
in the Restated Certificate. 
 3.5 Directors’ and Officers’ Insurance. The Company shall use
its commercially reasonable efforts to maintain, from financially sound and reputable insurers, directors and officers liability insurance in an amount and on terms and conditions satisfactory to the Board, including each Preferred Director, until
such time as the Board (including each Preferred Director) determines that such insurance should be discontinued. 
 3.6 Board
Matters. The Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse non-employee directors for all reasonable documented expenses incurred in attending
each meeting of the Board or any committee thereof. All non-employee directors shall be compensated uniformly for service on the Board. 

3.7 Proprietary Information and Inventions Agreements. The Company shall require all employees and consultants to execute and deliver a
Proprietary Information and Inventions Agreement in substantially the form approved by the Board or a consulting agreement containing substantially similar proprietary rights assignment and confidentiality provisions. 

  
 17 

 3.8 Employee Agreements. Unless approved by the Board including at least one
(1) Preferred Director, all future employees of the Company who shall purchase, or receive options to purchase, shares of Common Stock following the date hereof shall be required to execute stock purchase or option agreements providing for
(a) vesting of shares over a four (4) year period with the first twenty five percent (25%) of such shares vesting following twelve (12) months of continued employment or services, and the remaining shares vesting in equal monthly
installments over the following thirty six (36) months thereafter and (b) a one hundred and eighty (180)-day lockup period (plus an additional period of up to eighteen (18) days) in connection
with the Initial Public Offering. The Company shall retain a right of first refusal on transfers until the Initial Public Offering and the right to repurchase unvested shares at cost. 

3.9 Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Preferred Stock, as
well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in
Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the
Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In
addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating whether (and what portion of) such
Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s possession as is
reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. 

3.10 Right to Conduct Activities. The Company hereby acknowledges and agrees that certain of the investors, together with their
Affiliates constituting private equity or venture capital funds, including, but not limited to Deerfield Private Design Fund IV, L.P. and its Affiliates, (collectively, the “Investor Funds”), directly or indirectly, from time to
time may (a) make or hold investments in, or trade in securities of, companies that are or may become engaged in activities that are competitive with the Company’s business, as it is currently conducted or as it may be conducted in the
future, and (b) engage in other activities which may be deemed competitive with the Company’s business, as it is currently conducted or as it may be conducted in the future. The Company hereby agrees that the Investor Funds shall not be
liable to the Company for any claim arising out of, or based upon any such activities, including, without limitation (A) an investment by any of the Investor Funds, directly or indirectly, in any entity competitive with the Company or
(B) any other actions taken by any of the Investor Funds, or any partner, officer or other representative thereof, to assist any such competitive company, whether or not such action has a detrimental effect on the Company; provided, however,
that the foregoing shall not relieve any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. The Company 

  
 18 

 
acknowledges that the Investor Funds are in the business of private equity investing and therefore review the business plans and related proprietary information of many enterprises, including
enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude, create an obligation or duty, or in any way restrict any of the Investor Funds from evaluating
or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise, whether or not such enterprise has products or services which compete with those of the Company.

 3.11 Termination of Certain Covenants. The covenants set forth in Sections 3.6, 3.7 and 3.8 shall terminate and be of no
further force or effect upon the consummation of (a) the Company’s Qualified Public Offering or (b) a Liquidation Event (other than an Asset Sale), in each case, as such terms are defined in the Restated Certificate. 

4. Miscellaneous. 
 4.1
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any
shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement. 
 4.2 Governing Law. This Agreement shall be governed
by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California. 

4.3 Counterparts; Electronic Signature. This Agreement may be executed by electronic signature and in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including pdf) or other transmission method and
any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 4.4
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

4.5 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively
given upon the earlier to occur of actual receipt or: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on
the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All notices and other communications shall be sent to the Company and to the other parties at the addresses set forth on the signature pages hereto, as applicable (or at such other
addresses as shall be specified by notice given in accordance with this Section 4.5). 

  
 19 

 4.6 Expenses. If any action at law or in equity is necessary to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.7 Entire Agreement; Amendments. This Agreement (including the Exhibits hereto, if any) constitutes the full and entire understanding
and agreement among the parties with regard to the subjects hereof and thereof. Any term of this Agreement (other than Section 3.1, Section 3.2, Section 3.3 and Section 3.4) may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Investors holding a majority of the Registrable Securities, including a majority of
the shares of Series B Preferred Stock then held by the Investors; provided, however, that in the event that such amendment or waiver adversely affects the obligations or rights of the Common Holders in a different manner than the
other Holders, such amendment or waiver shall also require the written consent of the Common Holders holding a majority of the shares of Common Stock then held by all Common Holders. The provisions of Section 3.1, Section 3.2 and
Section 3.3 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities
then held by all of the Major Investors. The provisions of Section 3.4 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the ROFO
Investors holding a majority of the Registrable Securities then held by all of the ROFO Investors including holders of a majority of the Series B Preferred Stock held by the ROFO Investors; provided, however, that in the event of any
such amendment or waiver of the provisions of Section 3.4, a ROFO Investor who has, as of the date of any applicable offering, previously invested at least $12,000,000 in the Company’s Preferred Stock, shall continue to be entitled to its
right of first offer under Section 3.4 to the extent, and in the same relative percentage of such ROFO Investor’s pro rata rights (but for such amendment or waiver), that any other ROFO Investor or holder of Preferred
Stock or any of their respective affiliates is permitted to participate in such offering. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities, each future holder of all
such Registrable Securities and the Company. 
 4.8 Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 4.9
Aggregation of Stock. All shares of Registrable Securities held or acquired by affiliated entities (including affiliated venture capital funds or venture capital funds under common investment management) or Persons shall be aggregated
together for the purpose of determining the availability of any rights under this Agreement. 

  
 20 

 4.10 Additional Investors. Notwithstanding Section 4.7, no consent shall be
necessary to add additional Investors as signatories to this Agreement and to update Schedule A accordingly, provided that such Investors have (a) purchased Series B Preferred Stock, whether pursuant to the Purchase Agreement or
otherwise and (b) executed and delivered an additional counterpart signature page to this Agreement. 
 4.11 Effect on Prior
Agreement. The Prior Agreement is hereby amended and restated in its entirety and shall be of no further force or effect. 

[Remainder of page intentionally left blank] 

  
 21 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	SINGULAR GENOMICS SYSTEMS, INC.
		
	By:	 	/s/ Andrew Spaventa
		 	Andrew Spaventa, Chief Executive Officer
	
	Address:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	COMMON HOLDERS:
	
	 /s/ Andrew Spaventa

	 Andrew Spaventa

	
	 Address:

	
	 Email:

	
	 /s/ Eli Glezer

	 Eli Glezer

	
	 Address:

	
	 Email:

	
	 /s/ David Barker

	 David Barker

	
	 Address:

	
	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
		
	By:	 	Deerfield Mgmt IV, L.P. General Partner
		
	By:	 	J.E. Flynn Capital IV, LLC General Partner
		
	By:	 	/s/ David J. Clark
	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	 c/o Deerfield Management Company, L.P.
  

and
  

c/o Deerfield Management Company, L.P.

	
	With a required copy to:
	
	McDermott Will & Emery LLP

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	DOMAIN PARTNERS IX, L.P.
	By:	 	One Palmer Square Associates IX, L.L.C.,
its General Partner
		
	By:	 	/s/ Lisa A. Kraeutler
		 	Lisa A. Kraeutler
		 	Attorney-in-Fact
	
	Address:
	
	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ARCH VENTURE FUND IX, L.P.
		
	By:	 	ARCH Venture Partners IX, L.P.
	Its:	 	General Partner
	By:	 	ARCH Venture Partners IX, LLC
	Its:	 	General Partner
		
	By:	 	/s/ Mark McDonnell
	Name:	 	Mark McDonnell
	Its:	 	Managing Director
	
	Address:
	
	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	LC HealthCare Fund I, L.P.
		
	By:	 	/s/ Authorized Signatory
		
	Name:	 	  Authorized Signatory

		
	Title:	 	  Authorized Signatory

	
	Address:
	
	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Axon Ventures X, LLC
		
	By:	 	 Axon Managers, LLC
 its
Manager

		
	By:	 	/s/ Afif Khoury
		 	Afif Khoury, Manager
	
	Address:
	Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Athena Ventures I LLC
		
	By:	 	/s/ David Mayhew
		
	Name:	 	David Mayhew
		
	Title:	 	Authorized Signatory
		
	Address:	 	
	 Copy:
	 	

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Giant Plan Limited
		
	By:	 	/s/ Authorized Signatory
		
	Name:	 	 Authorized Signatory

		
	Title:	 	 Authorized Signatory

		
	Address:	 	
	 Email:
	 	

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Hui Veggie LLC
		
	By:	 	/s/ Graham Monroe
		
	Name:	 	Graham Monroe
		
	Title:	 	Member
		
	Address:	 	
		
	 Email:
	 	

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Mitchell and Elizabeth Siegler 1998 Family Trust
		
	By:	 	/s/ Mitchell Siegler
		
	Name:	 	Mitchell Siegler
		
	Title:	 	Trustee
		
	Address:	 	
		
	 Email:
	 	

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Section 32 Fund 2, LP
	By:	 	Section 32 GP 2, LLC, its general partner
		
	By:	 	/s/ Jennifer L. Kercher
	Name:	 	Jennifer L. Kercher
	Title:	 	Chief Operating Officer
	
	 Address:

	 Email:

		
	 Attn:
	 	Chief Operating Officer

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Broad Street Principal Investments, L.L.C.
		
	By:	 	/s/ Nick Giovanni
	Name:	 	Nick Giovanni
	Title:	 	Vice President
		
	 Address:
	 	
	 Email:
	 	

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	COATUE EARLY STAGE FUND LP
	By: Coatue Early Stage GP LLC, its General Partner
		
	Signature:	 	/s/ Zachary Feingold
		
	Print Name:	 	Zachary Feingold
		
	Title:	 	Authorized Signatory
	
	 Address:

	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	COATUE CT 50 LLC
		
	Signature:	 	/s/ Zachary Feingold
		
	Print Name:	 	Zachary Feingold
		
	Title:	 	Authorized Signatory
	
	 Address:

	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	F-PRIME CAPITAL PARTNERS LIFE SCIENCES FUND VI LP
	
	By: F-Prime Capital Partners Life Sciences Advisors Fund VI LP, its general partner
	
	By: Impresa Holdings LLC, its general partner
	
	By: Impresa Management LLC, its managing member
		
	By:	 	/s/ Mary Bevelock Pendergast
	Name:	 	Mary Bevelock Pendergast
	Title:	 	Vice President
	
	 Address:

	 Attn:
	 	Mary Bevelock Pendergast
	
	 Email:

  
  

  
 Signature Page to
Singular Genomics Systems, Inc. 
 Amended and Restated Investors’ Rights Agreement 

 SCHEDULE A 

SCHEDULE OF INVESTORS 
 Domain Partners
IX, L.P. 
 ARCH Venture Fund IX, L.P. 
 LC Healthcare Fund I,
L.P. 
 Mitchell and Elizabeth Siegler 1998 Family Trust 
 Mark
V. Bowles and Kathleen A. Bowles Living Trust Dated July 9, 2004 
 Kevin Quinn 

Tao Jiang 
 Hui Veggie LLC 

Marc Lipschitz Profit Sharing Plan 
 Axon Ventures X, LLC 

Athena Ventures I LLC 
 GV 2017, L.P. 

Alexandria Venture Investments, LLC 
 Sea Lane Ventures, LLC 

Giant Plan Limited 
 G&H Partners 

The Pellini Family Trust 
 Jiang Zhao Family Trust 

The Brian Ahern Separate Property Trust 
 Thomas and Judith Tullie
Family Trust 
 Deerfield Private Design Fund IV, L.P. 
 Broad
Street Principal Investments, L.L.C. 
 Section 32 Fund 2, LP 

Coatue Early Stage Fund LP 
 Coatue CT 50 LLC 

F-Prime Capital Partners Life Sciences Fund VI LP 

 SCHEDULE B 

SCHEDULE OF COMMON HOLDERS 

Andrew Spaventa 
 Eli Glezer 

Jingyue Ju 
 David Barker 

 AMENDMENT TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Amendment To Amended And Restated Investors’ Rights Agreement (the “Amendment”) is made as of August 27, 2019,
by and among Singular Genomics Systems, Inc., a Delaware corporation (the “Company”), and the undersigned Investors and Common Holders. 

WHEREAS, the Company and the undersigned Investors and the Common Holders are parties to that certain Amended and Restated Investors’
Rights Agreement, dated June 27, 2019 (the “Investors’ Rights Agreement”); 
 WHEREAS, the Investors’ Rights
Agreement may be amended, and any provision therein waived, as set forth herein with the consent of the Company and the holders of a majority of the Registrable Securities (as such term is defined in the Investors’ Rights Agreement), including
a majority of the shares of Series B Preferred Stock then held by the Investors and the undersigned parties constitute the requisite majority to amend the Investors’ Rights Agreement; 

WHEREAS, the parties desire to amend the Investors’ Rights Agreement as set forth herein. 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS: 

1. Definitions. Unless otherwise indicated herein, words and terms which are defined in the Investors’ Rights Agreement shall have
the same meaning where used herein. 
 2. Confidentiality. A new Section 3.11 is hereby added to the Investors’ Rights
Agreement (with the former Section 3.11 being renumbered to Section 3.12), which new Section 3.11 reads as follows: 

“Section 3.11 Confidentiality. Each Investor agrees, severally and not jointly, that such Investor (a) will keep
confidential, (b) will not disclose, divulge or use for any purpose (other than to monitor its investment in the Company, in connection with evaluating other investment opportunities in the ordinary course of business or as specifically
permitted herein) and (c) will protect to the same degree as it protects its own similar confidential information any confidential information obtained from the Company pursuant to the terms of this Agreement (including, without limitation,
notice of the Company’s intention to file a registration statement), unless such confidential information (i) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.11 by such
Investor), (ii) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (iii) is or has been made known or disclosed to the Investor by a third party without a breach of
any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (A) to its attorneys, accountants, consultants and other professionals to the extent necessary
or reasonably appropriate to obtain their services in connection with monitoring its investment in the Company or interpreting, 

 
enforcing, or defending a claim against the Company, provided that such Persons are under a contractual or legal obligation to preserve the confidentiality of such information; (B) to any
prospective purchaser of any Registrable Securities or other securities of the Company from such Investor (other than an operating company engaged in a business competitive with the Company), if such prospective purchaser agrees to be bound by the
provisions of this Section 3.11 or other substantially similar provisions; (C) to any existing or prospective Affiliate (other than an operating company engaged in a business competitive with the Company), partner, member, stockholder or
wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and such Person is under a contractual or legal obligation to preserve the
confidentiality of such information; or (D) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure (if legally permitted) and takes reasonable steps to minimize the extent of any such
required disclosure (each Person contemplated by clause (A), (B) and (C), a “Permitted Disclosee”). Furthermore, nothing contained herein shall prevent any Investor or any Permitted Disclosee from (x) entering into any
business, entering into any agreement with a third party, or investing in or engaging in investment discussions with any other company (whether or not competitive with the Company), provided that such Investor or Permitted Disclosee does not, except
as permitted in accordance with this Section 3.11, disclose or otherwise make use of any proprietary or confidential information of the Company in connection with such activities, or (y) making any disclosures required by law, rule,
regulation or court or other governmental order. Additionally, the Company understands and acknowledges that in the regular course of business each Investor and any of their respective representatives currently may be invested in, may invest in or
may consider investments in companies that have issued securities that are publicly traded (each, a “Public Company”). Accordingly, the Company covenants and agrees that before providing material
non-public information about a Public Company (“Public Company Information”) to any Investor, the Company will use commercially reasonable efforts to provide prior written notice to the
compliance personnel at such Investor, as applicable, describing such information in reasonable detail. The Company shall not disclose Public Company Information to an Investor without written authorization from the applicable compliance personnel,
provided, however, that, the Company will be permitted to disclose agreements entered into with Public Companies in the ordinary course of business, such as routine customer, supplier, advertising and publishing agreements without such written
authorization.” 
 3. Continued Validity of the Investors’ Rights Agreement. Except as specifically modified hereby, the
Investors’ Rights Agreement shall continue in full force and effect as originally constituted and is ratified and affirmed by the parties hereto. 

4. Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Amendment shall inure to the benefit
of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of 

 
Registrable Securities). Nothing in this Amendment, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations or liabilities under or by reason of this Amendment, except as expressly provided in this Amendment. 
 5.
Governing Law. This Amendment shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California. 

6. Counterparts. This Amendment may be executed by electronic signature and in two (2) or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one (1) and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 7. Titles and Subtitles. The titles
and subtitles used in this Amendment are used for convenience only and are not to be considered in construing or interpreting this Amendment. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	COMPANY:
	
	SINGULAR GENOMICS SYSTEMS, INC.
		
	By:	 	 /s/ Andrew Spaventa

		 	Andrew Spaventa, Chief Executive Officer
	
	Address:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

	
	 COMMON HOLDERS:

	
	 /s/ Andrew Spaventa

	Andrew Spaventa
	
	Address:
	
	Email:
	
	 /s/ Eli Glezer

	 Eli Glezer

	
	Address:
	
	Email:
	
	 /s/ David Barker

	 David Barker

	
	Address:
	
	Email:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	 INVESTOR:

	
	 DEERFIELD PRIVATE DESIGN FUND IV, L.P.

		
	By:	 	 Deerfield Mgmt IV, L.P. 

		 	 General Partner

		
	By:	 	 J.E. Flynn Capital IV, LLC 

		 	 General Partner

		
	By:	 	 /s/ David J. Clark

	 Name:
	 	David J. Clark
	Title:	 	Authorized Signatory
	
	 C/O DEERFIELD MANAGEMENT

COMPANY, L.P.
 EMAIL: 

	
	 WITH A REQUIRED COPY TO: 

McDermott Will & Emery LLP

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	 INVESTOR:

	
	 DOMAIN PARTNERS IX, L.P.

	By: One Palmer Square Associates IX, L.L.C., its General Partner
		
	By:	 	 /s/ Lisa Kraeutler

		 	 Lisa A. Kraeutler

		 	Attorney-in-Fact
	
	Address:
	
	Email:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	 INVESTOR:

	
	LC HealthCare Fund I, L.P.
		
	By:	 	 /s/ Authorized Signatory

		
	Name:	 	 Authorized Signatory 

		
	Title:	 	 Authorized Signatory 

	
	Address:
	
	Email:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	 INVESTOR:

	
	 Athena Ventures I LLC

		
	By:	 	 /s/ David Mayhew

		
	Name:	 	 David Mayhew

		
	Title:	 	 Authorized Signatory

	
	Address:
	Copy:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	 INVESTOR:

	
	 ALEXANDRIA VENTURE INVESTMENTS, LLC, a Delaware limited liability company

	
	 By: ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member

		
	By:	 	 /s/ Aaron Jacobson

		
	Name:	 	         Aaron Jacobson

		
	Title:	 	         SVP – Venture Counsel

	
	Address:
	 Email:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	 INVESTOR:

	
	 Section 32 Fund 2, LP

	 By: Section 32 GP 2, LLC, its general partner

		
	By:	 	 /s/ Jennifer Kercher

	 Name: Jennifer L. Kercher 

	 Title: Chief Operating Officer 

	
	Address:
	 Email:

	
	Attn:        Chief Operating Officer

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
written above. 
  

			
	INVESTOR:
	
	COATUE EARLY STAGE FUND LP
	 By: Coatue Early Stage GP LLC, its General Partner

		
	Signature:	 	/s/ Zachary Feingold
	
	 Print Name: Zachary Feingold

	
	Title: Authorized Signatory
	
	Address:
	Email:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above. 

 

			
	INVESTOR:
	
	COATUE CT 50 LLC
		
	Signature:	 	/s/ Zachary Feingold
	
	 Print Name: Zachary Feingold

	
	Title: Authorized Signatory
	
	Address:
	Email:

  

  
 AMENDMENT
TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTEX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY,
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO PURCHASE STOCK 

Company: SINGULAR GENOMICS SYSTEMS, INC. 
 Number of
Shares: 32,289, plus all Additional Shares which Holder is entitled to purchase pursuant to Section 1.7 
 Type/Series of Stock: Series B
Preferred 
 Warrant Price: $2.3228 per share 
 Issue
Date: November 19, 2019 
 Expiration Date: November 19, 2029        See also
Section 5.1(b). 
 Credit Facility: This Warrant to Purchase Stock (“Warrant”) is issued in connection with that 

certain Loan and Security Agreement of even date herewith between Silicon 

Valley Bank and the Company (as amended, restated, supplemented or 

otherwise modified from time to time, the “Loan Agreement”). 

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any successor or permitted assignee or
transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of
the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant,
subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this Warrant to its parent company, SVB Financial Group. 

SECTION 1. EXERCISE. 
 1.1
Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto
as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or
other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. In no event shall an original ink-signed paper copy of this Warrant be required for any exercise
of a Holder’s rights hereunder, nor shall this Warrant or any physical copy thereof be required to be physically surrendered at the time of any exercise hereof. 

1.2 Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in
Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the
Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

	 	X  =	 Y(A-B)/A 

where: 
  

	 	X  =	 the number of Shares to be issued to the Holder; 

 

	 	Y  =	 the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered
to the Company in payment of the aggregate Warrant Price); 

  

	 	A  =	 the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

  

	 	B  =	 the Warrant Price. 

1.3 Fair Market Value. If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange,
inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall
be the closing price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common
stock is then traded in a Trading Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock
reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then
convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. 

1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired. 
 1.5 Replacement of Warrant. 

(a) Paper Original Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for
cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 
  

 

  
 2 

 (b) Electronic Original Warrant. If at any time this Warrant is rejected by any
person (including but not limited to, paying or escrow agents) or any such person fails to comply with the terms of this Warrant based on this Warrant being presented to such person as an electronic record, a printout thereof, or any signature
hereto being in electronic form, the Company, shall, promptly upon Holder’s request without indemnity, execute and deliver to Holder, in lieu of electronic original versions of this warrant, a new warrant of like tenor and amount in paper form
with original signatures. 
 1.6 Treatment of Warrant Upon Acquisition of Company. 

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the
stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. Notwithstanding the foregoing, the consummation of a bona fide equity financing in which no existing
stockholders of the Company sell shares shall not be deemed to be an Acquisition for purposes of this Warrant. 
 (b) Treatment of
Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a
“Cash/Public Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public
Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be deemed to be Cashless Exercised pursuant to Section 1.2 above as to all Shares effective
immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as
of the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in
accordance with Section 1.3 above would be less than or equal to the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will automatically expire immediately prior to the consummation of such
Cash/Public Acquisition. 
 (c) Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring,
surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the
unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

 
  

  
 3 

 (d) As used in this Warrant, “Marketable Securities” means securities
meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the
Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such
Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition.
Notwithstanding the foregoing provisions of this Section 1.6(d), securities held in escrow or subject to holdback to cover indemnification related claims in connection with such Acquisition shall be deemed to be Marketable Securities if they
would otherwise be Marketable Securities but for the fact that they are held in escrow or subject to holdback to cover indemnification related claims. 

1.7 Additional Shares. Upon the funding of each Growth Capital Advance under the Second Tranche and the Third Tranche (as such terms
are defined in the Loan Agreement), the Company shall be deemed to have automatically granted to Holder, in addition to the number of Shares which this Warrant can otherwise be exercised for by Holder, the right to purchase that number of additional
Shares, rounded upward to the nearest whole number, equal to (a) three percent (3.0%) of the principal amount of such Growth Capital Advance, divided by (b) the Warrant Price (such additional shares being called the “Additional
Shares”). 
 1.8 “Pay to Play”. In the event that any “pay to play” terms or conditions (i.e.
terms or conditions that require a holder of the Company’s Preferred Stock to purchase securities in a future round of equity financing or else lose the benefit of such rights, preferences and/or privileges such as anti-dilution protection
applicable to the shares of Preferred Stock issuable upon the exercise of this Warrant or have such shares of Preferred Stock automatically convert to common stock or convert to another class and series of the Company’s capital stock), are
triggered after the date hereof (a “Pay to Play Financing”), then in such event, this Warrant, only to the extent of Shares not previously exercised, shall automatically adjust to provide the Holder with the same securities and/or
rights that the Holder would have received had the Holder participated in the Pay to Play Financing to its full pro rata share with respect to the Preferred Stock issuable upon exercise of this Warrant (e.g., if this Warrant provides for the
purchase of Series B Preferred Stock, and the Company after the date hereof consummates a Pay to Play Financing in which those holders of Series B Preferred Stock who participate to their full pro rata share in such Pay to Play Financing become
entitled to exchange such Series B Preferred Stock for Series C Preferred Stock and those holders of Series B Preferred Stock who do not participate to their full pro rata share will have their Series B Preferred Stock converted into Common Stock,
then this Warrant would automatically adjust to provide the right to purchase Series C Preferred Stock instead of Common Stock); provided, however, that in no event shall the value of the adjusted Warrant exceed the value of the Warrant as of the
date immediately prior to the “Pay to Play” Financing (calculated based on the multiplying the number of shares by the exercise price set forth on the first page hereof). 

 
  

  
 4 

 SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the
Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and
property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater
number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification
or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the
Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the
number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the
provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events. 

2.3 Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the
event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including, without limitation, in
connection with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on which all outstanding
shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding on the date of such conversion, and the
Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to further adjustment thereafter from time
to time in accordance with the provisions of this Warrant. 
 2.4 Adjustments for Diluting Issuances. Without duplication of any
adjustment otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s
Articles or Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 
  

 

  
 5 

 2.5 No Fractional Share. No fractional Share shall be issuable upon exercise of this
Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in
cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company,
at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon
written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment. 

SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the
Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold. 

(b) All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares,
shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities as
will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

(c) The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the Issue
Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time to: 

(a) declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or
other securities and whether or not a regular cash dividend; 
 (b) offer for subscription or sale pro rata to the holders of the
outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual participation or pre-emptive rights); 

 
  

  
 6 

 (c) effect any reclassification, exchange, combination, substitution, reorganization or
recapitalization of the outstanding shares of the Class; 
 (d) effect an Acquisition or to liquidate, dissolve or wind up; or 

(e) effect an IPO; 
 then, in connection with
each such event, the Company shall give Holder: 
 (1) in the case of the matters referred to in (a) and (b) above, at
least seven (7) Business Days prior written notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the
holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any; 
 (2)
in the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the
Class will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in
connection with such event giving rise to the notice); and 
 (3) with respect to the IPO, at least seven (7) Business
Days prior written notice of the date on which the Company proposes to publicly file its registration statement in connection therewith. 
 Company will
also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. 

SECTION 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Shares. 
 4.2 Disclosure of Information. Holder is aware of the Company’s business affairs and financial
condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has
had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such
information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 
  

  
 7 

 4.3 Investment Experience. Holder understands that the purchase of this Warrant and
its underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant
and its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting
personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

 4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated
under the Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been
registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the
Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available.
Holder is aware of the provisions of Rule 144 promulgated under the Act. 
 4.6 Market Stand-off
Agreement. The Holder agrees that the Shares shall be subject to the Market Standoff provisions in Section 2.12 of the Investor Rights Agreement or similar agreement. 

4.7 No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. 

SECTION 5. ISCELLANEOUS. 
 5.1
Term and Automatic Conversion Upon Expiration. 
 (a) Term. Subject to the provisions of Section 1.6 above, this Warrant
is exercisable in whole or in part at any time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 

(b) Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or
other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be
exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such
other securities) issued upon such exercise to Holder. 
  
  

  
 8 

 5.2 Legends. The Shares (and the securities issuable, directly or indirectly, upon
conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 
 THE SHARES
EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE
ISSUER TO SILICON VALLEY BANK DATED NOVEMBER 19, 2019 MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE
OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares
issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company
shall not require Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited
investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4 Transfer Procedure. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will transfer all of this
Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of the
terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, SVB Financial Group and any subsequent Holder may transfer all or part of this
Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, SVB Financial Group
or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to
the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. Notwithstanding
any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other
securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

 
  

  
 9 

 5.5 Notices. All notices and other communications hereunder from the Company to the
Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt
if given by electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have
been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company
receives notice of a change of address in connection with a transfer or otherwise: 
 SVB Financial Group 

Attn: Treasury Department 
 3003
Tasman Drive, HC 215 
 Santa Clara, CA 95054 

Telephone: 
 Email address:
derivatives@svb.com 
 Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

SINGULAR GENOMICS SYSTEMS, INC. 

Attn: Drew Spaventa, CEO 
 10931
N. Torrey Pines Road 
 La Jolla, CA 92037 

Telephone: 
 Email: 

With a copy to, which shall not constitute notice to the Borrower: 

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 

c/o Jeffrey Thacker 
 3570
Carmel Mountain Road 
 Suite 200 

San Diego, CA 92130 
 Email:
jthacker@gunder.com 
 5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either
generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 
  

 

  
 10 

 5.8 Counterparts; Electronic Signatures; Status as Certificated Security. This
Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement. Company, Holder and any other party hereto may execute this Warrant by electronic means and each party hereto recognizes and accepts the use
of electronic signatures and records by any other party hereto in connection with the execution and storage hereof. To the extent that this Warrant or any agreement subject to the terms hereof or any amendment hereto is executed, recorded or
delivered electronically, it shall be binding to the same extent as though it had been executed on paper with an original ink signature. The fact that this Warrant is executed, signed, stored or delivered electronically shall not prevent the
transfer by any Holder of this Warrant pursuant to Section 5.4 or the enforcement of the terms hereof. This Warrant, and any copies hereof, shall NOT be deemed to be a “certificated security” within the meaning of Section 8102
(a)(4) of the California Commercial Code. Physical possession of the original of this Warrant or any paper copy thereof shall confer no special status to the bearer thereof. 

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. 
 5.10 Headings. The headings in this Warrant are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11 Business Days.
“Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 
 [Remainder of
page left blank intentionally] 
 [Signature page follows] 
  

 

  
 11 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be
executed by their duly authorized representatives effective as of the Issue Date written above. 
 “COMPANY” 

SINGULAR GENOMICS SYSTEMS, INC. 
  

			
	By:	 	 /s/ Drew Spaventa

			
	Name:	 	 Drew Spaventa

			
	Title:	 	CEO

 “HOLDER” 
 SILICON
VALLEY BANK 
  

			
	By:	 	 /s/ Igor DaCruz

			
	Name:	 	 Igor DaCruz

			
	Title:	 	Director

 APPENDIX 1 

NOTICE OF EXERCISE 
 1. The undersigned
Holder hereby exercises its right to purchase ___________ shares of the Common/Series _____ Preferred [circle one] Stock of SINGULAR GENOMICS SYSTEMS, INC. (the “Company”) in accordance with the attached Warrant to Purchase Stock,
and tenders payment of the aggregate Warrant Price for such shares as follows: 

[        ]        Check in the amount of
$                 payable to the order of the Company enclosed herewith 

[        ]        Wire transfer of immediately available funds to the
Company’s account 
 [        ]        Cashless Exercise pursuant to
Section 1.2 of the Warrant 
 [        ]        Other [Describe] 

2. Please issue a certificate or certificates representing the Shares in the name specified below: 

 

					
	               	 	 	  	
		 	Holder’s Name	  	
			
		 	 	  	
			
		 	 	  	
		 	(Address)	  	

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and
warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof. 
  

			
	HOLDER:

 
			
		
	By:	 	   

 
			
		
	Name:	 	   

 
			
		
	Title:	 	   

 
			
		
	(Date):	 	   

  
 Appendix 1 

 SCHEDULE 1 

Company Capitalization Table 

[omitted] 

  
 Schedule 1 

 FIRST AMENDMENT 

TO 
 WARRANT TO PURCHASE
STOCK 
 This First Amendment to Warrant to Purchase Stock (this “Amendment”) is entered into as of May 1, 2020, by and between SVB
Financial Group (“Holder”) and Singular Genomics Systems, Inc., a Delaware corporation (“Company”) whose address is 10931 N. Torrey Pines Road, La Jolla, CA 92037. 

RECITALS 

A. Company executed and delivered to Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Stock dated
November 19, 2019 (the “Warrant”), in connection with that certain Loan and Security Agreement of even date therewith, between Bank and Borrower (as amended, restated, supplemented or otherwise modified from time to time, the
“Loan Agreement”), which Warrant was then assigned by Bank to Holder. 
 B. Borrower has requested that Holder amend the
Warrant to state the number of additional shares that Holder has the right to purchase under the Warrant, as automatically granted under the terms of the Warrant (as in effect immediately prior to this Amendment) upon the funding of an advance under
the Second Tranche (as defined in the Loan Agreement) in an amount equal to Seven Million Five Hundred Thousand Dollars ($7,500,000). 

C. Holder has agreed to so amend the Warrant, but only to the extent, in accordance with the terms and subject to the conditions set
forth below. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 

1. Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Warrant.

 2. Amendments to Warrant. 

2.1 Number of Shares. The Section titled “Number of Shares” on page 1 of the Warrant is amended in its entirety
and replaced with the following: 
 Number of Shares: A number equal to the sum of (a) 32,289 which Holder became
entitled to purchase as the Issue Date, plus (b) 96,867 which Holder became entitled to purchase as of March 23, 2020, plus (c) all Additional Shares which Holder is entitled to purchase pursuant to Section 1.7. 

2.2 Section 1.7 (Additional Shares). Section 1.7 is amended in its entirety and replaced with the following: 

  
 15 

 1.7 Additional Shares. Upon the funding of each Growth Capital
Advance under the Third Tranche (as such terms are defined in the Loan Agreement), Company shall be deemed to have automatically granted to Holder, in addition to the number of Shares which this Warrant can otherwise be exercised for by Holder, the
right to purchase that number of additional Shares, rounded upward to the nearest whole number, equal to (a) three percent (3.0%) of the principal amount of such Growth Capital Advance, divided by (b) the Warrant Price, subject to
adjustment in accordance with Section 2 below (such additional shares being called the “Additional Shares”). 
 2.3
Signature Block for Company. For clarity, the name of Company in the signature block of the Warrant is amended in its entirety and replaced with the following: 

SINGULAR GENOMICS SYSTEMS, INC. 

3. Limitation of Amendment. 

3.1 The amendments set forth in Section 2 above are effective for the purposes set forth herein and shall be limited precisely as
written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of the Warrant, or (b) otherwise prejudice any right or remedy which Holder may now have or may have in the future
under or in connection with the Warrant. 
 4. Integration. This Amendment and the Warrant represent the entire agreement
about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Warrant merge into
this Amendment and the Warrant. 
 5. Counterparts. This Amendment may be executed in any number of counterparts and all of
such counterparts taken together shall be deemed to constitute one and the same instrument. 
 [Signature page follows.] 

  
 16 

 IN WITNESS WHEREOF, the
parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above. 
  

									
	HOLDER	  		 	COMPANY
			
	SVB FINANCIAL GROUP	  		 	SINGULAR GENOMICS SYSTEMS, INC.
					
	 By:
	 	 /s/ David Busch
	  		 	 By:
	 	 /s/ Jeremy Ferrell

					
	 Name:
	 	 David Busch
	  		 	 Name:
	 	 Jeremy Ferrell

					
	 Title:
	 	 Sr. Manager, Corporate Investment & Funding
	  		 	 Title:
	 	 CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]